https://www.selleckchem.com/pr....oducts/ziritaxestat.
Postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) are the two main forms of functional dyspepsia (FD). Probiotics are a promising therapy for FD, but current data remains heterogeneous. This work aims to evaluate a probiotic combination of LR04 (DSM 16605), LPS01 (DSM 2198, LP01 (LMG P-21021), and subsp. LDD01 (DMS 22106), alone or together with other pharmacological therapies, for clinical improvement of symptoms associated with FD. Patients with FD were enrolled and divided into two groups PDS and EPS. Pro
Like
Comment
Share
